Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of $18.75 billion. The enterprise value is $25.27 billion.

Market Cap	18.75B
Enterprise Value	25.27B

Important Dates

The last earnings date was Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	May 16, 2025

Share Statistics

Royalty Pharma has 562.24 million shares outstanding. The number of shares has decreased by -1.86% in one year.

Current Share Class	421.37M
Shares Outstanding	562.24M
Shares Change (YoY)	-1.86%
Shares Change (QoQ)	-1.85%
Owned by Insiders (%)	11.59%
Owned by Institutions (%)	77.81%
Float	372.38M

Valuation Ratios

The trailing PE ratio is 13.61 and the forward PE ratio is 7.04. Royalty Pharma's PEG ratio is 0.63.

PE Ratio	13.61
Forward PE	7.04
PS Ratio	6.55
Forward PS	6.13
PB Ratio	2.12
P/TBV Ratio	2.81
P/FCF Ratio	n/a
P/OCF Ratio	6.94
PEG Ratio	0.63

Financial Ratio History

Enterprise Valuation

EV / Earnings	23.13
EV / Sales	11.16
EV / EBITDA	n/a
EV / EBIT	13.30
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.78.

Current Ratio	1.56
Quick Ratio	1.56
Debt / Equity	0.78
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	7.71

Financial Efficiency

Return on equity (ROE) is 18.00% and return on invested capital (ROIC) is 7.11%.

Return on Equity (ROE)	18.00%
Return on Assets (ROA)	7.04%
Return on Invested Capital (ROIC)	7.11%
Return on Capital Employed (ROCE)	11.57%
Revenue Per Employee	$22.87M
Profits Per Employee	$11.04M
Employee Count	99
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +18.74% in the last 52 weeks. The beta is 0.48, so Royalty Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.48
52-Week Price Change	+18.74%
50-Day Moving Average	32.49
200-Day Moving Average	29.23
Relative Strength Index (RSI)	59.17
Average Volume (20 Days)	3,830,754

Short Selling Information

The latest short interest is 18.59 million, so 3.31% of the outstanding shares have been sold short.

Short Interest	18.59M
Short Previous Month	20.57M
Short % of Shares Out	3.31%
Short % of Float	4.99%
Short Ratio (days to cover)	3.94

Income Statement

In the last 12 months, Royalty Pharma had revenue of $2.26 billion and earned $1.09 billion in profits. Earnings per share was $2.45.

Revenue	2.26B
Gross Profit	2.24B
Operating Income	1.90B
Pretax Income	673.24M
Net Income	1.09B
EBITDA	n/a
EBIT	1.90B
Earnings Per Share (EPS)	$2.45

Full Income Statement

Balance Sheet

The company has $1.10 billion in cash and $7.62 billion in debt, giving a net cash position of -$6.52 billion or -$11.59 per share.

Cash & Cash Equivalents	1.10B
Total Debt	7.62B
Net Cash	-6.52B
Net Cash Per Share	-$11.59
Equity (Book Value)	9.79B
Book Value Per Share	15.72
Working Capital	660.39M

Full Balance Sheet

Cash Flow

Operating Cash Flow	2.70B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 99.04%, with operating and profit margins of 83.95% and 48.26%.

Gross Margin	99.04%
Operating Margin	83.95%
Pretax Margin	78.12%
Profit Margin	48.26%
EBITDA Margin	n/a
EBIT Margin	83.95%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 2.64%.

Dividend Per Share	$0.88
Dividend Yield	2.64%
Dividend Growth (YoY)	4.88%
Years of Dividend Growth	5
Payout Ratio	35.89%
Buyback Yield	1.86%
Shareholder Yield	4.50%
Earnings Yield	5.83%
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for Royalty Pharma is $42.50, which is 27.42% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$42.50
Price Target Difference	27.42%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	6.61%
EPS Growth Forecast (5Y)	34.92%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.7 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.7
Piotroski F-Score	5